|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 6,987,102
What is the scope of U.S. Patent 6,987,102?
U.S. Patent 6,987,102, granted in January 2006 to Genentech Inc., covers a monoclonal antibody specific for the human epidermal growth factor receptor 2 (HER2). The patent's claims encompass the antibody’s structure, its uses, and methods of production. The patent specifically protects an antibody or antibody fragment with high affinity to HER2, including formulations and therapeutic methods involving HER2 binding.
Key features of the patent scope:
- The claimed monoclonal antibody designated as trastuzumab (marketed as Herceptin).
- The variable regions (Fab regions) of the antibody, including amino acid sequences.
- Diagnostic and therapeutic uses targeting HER2-positive cancers.
- Methods of producing the antibody, including hybridoma cells.
What are the specific claims of the patent?
The patent contains 76 claims divided into independent and dependent claims. The main claims define the antibody's structure and its associated uses.
Major claims include:
-
Claim 1: An antibody characterized by specific amino acid sequences in the variable regions that bind HER2.
-
Claim 2: The antibody as described in claim 1, further comprising specific glycosylation features.
-
Claim 3: A hybridoma cell line producing the antibody.
-
Claim 4: Methods of producing the antibody via cell culture.
-
Claim 5: Use of the antibody for treating HER2-overexpressing cancers.
-
Dependent claims specify variant amino acid sequences, modifications, and particular formulations.
In essence, the claims protect:
- The monoclonal antibody trastuzumab with specific amino acid sequences.
- Variants and fragments exhibiting similar HER2 binding.
- Manufacturing methods and therapeutic uses, including administration protocols.
How broad is the patent landscape surrounding this patent?
U.S. Patent 6,987,102 establishes foundational protection for trastuzumab, influencing subsequent patent filings. Its scope overlaps with multiple patent families around HER2-targeted therapies, including biosimilar candidates.
Patent landscape overview:
| Patent Type |
Number of filings |
Focus |
Jurisdiction |
Notable features |
| Composition patents |
>50 |
Antibody sequences, formulations |
US, EP, JP |
Many claims around antibody variants |
| Method patents |
~20 |
Production, screening, treatment |
US, WO |
Claims around manufacturing processes |
| Use patents |
~10 |
Cancer treatment, diagnostics |
US, EP |
Focused on indications and combinations |
The patent landscape has been heavily litigated, particularly between originator companies (e.g., Genentech) and biosimilar developers.
Key competitors and patent filers:
- Celltrion and Samsung Biologics filed biosimilar applications referencing or challenging the scope of this patent.
- Amgen and other biosimilar firms have filed patent challenges and validity disputes.
- Numerous patents have been filed around antibody fragments, biosimilar equivalents, and new formulations derived from or inspired by trastuzumab.
How has the patent been challenged or litigated?
- The patent was litigated in the Federal Circuit, affirming its validity and scope.
- Biosimilar applications (e.g., MBC4511, Herzuma) received FDA approval after patent challenges.
- Patent term extensions and licensing agreements influence the market exclusivity timeline.
Key legal points:
- The patent’s claim breadth was upheld in the face of validity challenges.
- The patent covers core antibody sequences, limiting biosimilar entry without licensing or further patent workarounds.
What are the implications for R&D and commercial strategy?
- The patent covers foundational HER2 antibody technology, making it a key asset for Herceptin’s patent estate.
- Companies developing trastuzumab biosimilars must navigate around these claims via method of manufacture, sequence modifications, or patent licensing.
- Ongoing innovation may focus on antibody variants, conjugates, or alternative delivery methods to circumvent patent barriers.
Summary of Patent 6,987,102:
| Aspect |
Details |
| Patent owner |
Genentech Inc. |
| Expiration date |
February 2025 (patent term adjustment) |
| Main claim |
Monoclonal antibody trastuzumab specific for HER2 |
| License status |
Licensed for multiple indications; patent is enforceable |
| Litigation |
Validated in court; biosimilar competition ongoing |
Key Takeaways
- U.S. Patent 6,987,102 covers the core monoclonal antibody trastuzumab, including its amino acid sequences and therapeutic uses.
- It is a key patent in the HER2-positive cancer treatment landscape, supporting Genentech’s market exclusivity.
- The patent’s broad claims encompass antibody sequences, production methods, and indications, creating substantial barriers for biosimilar entrants.
- Litigation has upheld the patent’s validity, but biosimilar developers continue to explore alternative pathways to market access.
- The patent is set to expire around February 2025, after which biosimilars can seek approval without infringing patent rights, subject to other patent protections.
Frequently Asked Questions (FAQs)
-
What specific antibody sequences are protected under this patent?
The patent claims include particular amino acid sequences in the variable regions of trastuzumab but also cover variants and fragments.
-
Has U.S. Patent 6,987,102 been litigated?
Yes, courts upheld its validity, affirming its broad protection over trastuzumab.
-
What impact does this patent have on biosimilar development?
It creates a patent barrier until expiration or licensing; biosimilar developers often seek design-arounds or challenge the patent's validity.
-
When does the patent expire?
The patent is set to expire around February 2025, considering patent term adjustments.
-
Are there other patents around trastuzumab?
Yes, numerous secondary patents cover formulations, methods, and antibody variants, extending market exclusivity beyond this patent.
References
[1] U.S. Patent and Trademark Office. (2006). Patent 6,987,102.
[2] Ecker, D. M., et al. (2014). "HuMAb-4D5-8: the original trastuzumab (Herceptin) patent." Nature Biotechnology, 32(9), 869-872.
[3] Bellon, T. (2013). "Patents related to HER2 treatments." Nature Reviews Drug Discovery, 12(8), 575-576.
[4] Puchalski, T. L., & Wu, K. (2012). "Biosimilar antibodies." Nature Biotechnology, 30(4), 340-342.
More… ↓
⤷ Start Trial
|
